Inicio/Acciones/RVMD

RVMD

USD

Revolution Medicines Inc. Common Stock

$58.570+0.580 (1.000%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$57.990

Máximo

$59.680

Mínimo

$57.740

Volumen

2.37M

Fundamentos de la Empresa

Capitalización de Mercado

10.9B

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

2.19M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $29.17Actual $58.570Máximo $62.4

Noticias Relacionadas

3 nov 2025 · 14:20

Analyst Upgrades

RBC Capital Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $77

RBC Capital analyst Leonid Timashev initiates coverage on Revolution Medicines with a Outperform rating and announces Price Target of $77.

RBC Capital Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $77

27 oct 2025 · 12:00

GlobeNewswire

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

22 oct 2025 · 16:12

GlobeNewswire

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today